US/UK/Canada

Share

Links

Quotes

First of all, it is an honor to be recognized by ESMO, and we are thrilled to exhibit our promising results for OT-1096 for the first time. Even more so, being part of changing the treatment landscape for cancer at this time is exciting for us: the 2018 Nobel Prize in Medicine was awarded for pioneering work in immunooncology and we see more and more traction and exciting results from novel immunomodulatory small molecules, such as ours, with the capacity to favorably change the immune system inside tumors.
Prof. Owe Orwar, CEO at Oblique Therapeutics.
Pick a time period -
Tags ( Active)

Oblique Therapeutics will be presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020

Gothenburg, Sweden, October 24, 2019 – Oblique Therapeutics AB announces that Sreesha P Srinivasa is on the list of invited speakers who will be presenting at the RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020.Sreesha P Srinivasa, Senior Vice President at Oblique Therapeutics will be presenting the company’s KRAS antibody program, targeting KRAS driven malignancies such as lung and colon cancer, at the summit early next year. The summit unites experts in the RAS field; big pharma, biotech and academia. They are all trying to develop medicines targeting RAS, a

Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine

Gothenburg, Sweden, July 17, 2019 – Oblique Therapeutics, a Swedish biotech focusing on generating novel therapeutic antibodies towards severe diseases such as cancer and pain, has been honored as one of the most promising biotech startup in Europe 2019 by StartUp City magazine. An interview with the CEO, Owe Orwar is featured on the cover story of the BioTech special issue published this month.StartUp City Magazine: “Oblique Therapeutics is uncovering medical breakthroughs in antibody therapeutics using its proporietary technology platform AbiprotTM ”. The AbiprotTM technology enables the

Oblique Therapeutics present tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO

Gothenburg, 09 Oct 2018 – Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, today announced that it will present new promising preclinical data for the drug candidate OT-1096 in triple-negative breast cancer (TNBC) at the largest oncology congress in Europe, the European Society for Medical Oncology (ESMO), held 19-23 October in Munich, Germany.The new data of the first-in-class anti-cancer agent OT-1096 shows promising preliminary results with improved tumor growth inhibition compared to pembrolizumab, one of the blockbuster drugs

Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer

The Gothenburg, Sweden based biotech company Oblique Therapeutics AB today announced that the world-leading medical journal Science Translational Medicine in its latest issue has published promising preclinical research results on a new type of molecules against advanced cancer. The results are based on a collaboration with Professor Elias Arnér's research group at Karolinska Institute in Stockholm. In the article, titled Irreversible Inhibition of Cytosolic Thioredoxin Reductase 1 as a Mechanistic Basis for Anticancer Therapy, the researchers show that tumor growth is effectively

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe